Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.50 |
| ▸ | WNT3A | P56704 | 5/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037657 | 0.83 | AKR1C3 (0.54) | MAPTAOC3ALKALDH1A1 | |
| SCHEMBL29544175 | 0.83 | CASP6 (0.64) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL2450248 | 0.83 | CASP6 (0.64) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL1433299 | 0.83 | CHRNB2 (0.55) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL13434094 | 0.81 | CASP6 (0.53) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL1912372 | 0.81 | GFER (0.54) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL11977015 | 0.80 | CASP6 (0.53) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL2069135 | 0.80 | CASP6 (0.53) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL16437223 | 0.80 | CASP6 (0.53) | CASP6GFERMAPTMEN1KMT2A | |
| SCHEMBL6363304 | 0.80 | MEN1 (0.65) | MAPTMEN1KMT2AWNT3AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2611798-B1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8975260-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, TYK2, LCK | CASP6 977/4885GFER 4089/4885MAPT 966/4885 |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CASP6 2085/4885GFER 3327/4885MAPT 2154/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | CASP6 1523/4885GFER 2777/4885MAPT 4092/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | CASP6 1522/4885GFER 2778/4885MAPT 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.